Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Octave Specialty Group, Inc. (OSG)
NYSEFinancialsInsurance - SpecialtySnapshot 2026-11-04
$5.22+4.19%
Close 2026-11-04 · 1-day change
NYSEFinancialsInsurance - SpecialtySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
0.57 → 0.57 EPS · FY ending Dec 31, 2027 · 2 analysts
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
Change in the same fiscal period’s mean EPS estimate from Oct 5, 2026 to Nov 4, 2026: (new ÷ prior − 1). Contributor count changed from 2 to 2; this is not the number of analysts revising. The ±10% axis is a display range.
The EPS and P/E reference is not available for OSG yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Improve free cash flow yield | A supporting condition in Octave Specialty Group, Inc.'s published investment case. The stated target is Free cash flow yield improves to >= 0% within next 4 quarters. | Broken | Free cash flow yield remains below -10% after next 4 quarters | Free cash flow yield: -26.22% As of 2026-11-04; trailing twelve months. The target timing and basis require a separate assessment. Nov 4, 2026-26.22 percent · calculatedLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 9, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
OSG is an execution-dependent growth business, not a proven durable compounder: results are currently loss-making and recent performance is weak. The long-term thesis is on watch, with growth priorities progressing but insurance profitability and the newer AI effort still needing proof.
The evidence describes OSG as cheap versus peers, while its valuation has risen recently and the model’s expectations gap is negative, meaning expectations appear demanding relative to the evidence. Pricing fragility is rated low, but confidence in the valuation read is medium.
Near term, strong organic growth is showing up in Insurance Distribution, while Everspan’s combined ratio has improved but remains above 100%, indicating underwriting losses. The August earnings miss and weak performance versus the industry cohort are risks; the chance of a miss is assessed as low, with smaller size and recent peer misses noted as cautions. Management’s AI underwriting platform is early stage, with no measured financial impact yet.
Over the multi-year view, the thesis depends on sustaining organic growth and improving Everspan’s combined ratio by 2027. Near term, a guidance cut would be a meaningful negative, while continued earnings strength from sector bellwethers could support the sector backdrop. Interest-rate cuts are another risk identified in the evidence.
OSG has evidence of strong growth and progress in underwriting, but losses, weak recent performance, and execution uncertainty leave the 1-3 year thesis on watch. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Continue positive earnings trend |
| A primary condition in Octave Specialty Group, Inc.'s published investment case. The stated target is EPS >= $0.45 in FY26 and EPS >= $0.86 in FY27. |
| Broken |
| EPS falls below $0.30 in FY26 or below $0.60 in FY27 |
Diluted EPS: $-0.33 per share FY2026-Q2; GAAP. Published target: EPS >= $0.45 in FY26 and EPS >= $0.86 in FY27. Reported actuals cannot certify a consensus target without an explicit period and accounting-basis binding. Aug 6, 2026-0.33 USD/share · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Achieve strong organic revenue growth | A primary condition in Octave Specialty Group, Inc.'s published investment case. The stated target is >=25% YoY revenue growth for FY26. | Intact | YoY revenue growth falls below 15% in FY26 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 2 of 2 supplied quarters. Management reported: “Claude LeBlanc, President and Chief Executive Officer of Octave, said "Our core Insurance Distribution business delivered another quarter of strong performance led by revenue growth of 77% and organic revenue growth of 44%.” “"Our core Insurance Distribution business delivered 92% revenue growth, 42% organic growth, the rest from our recent ArmadaCare acquisition.” Delivery assessment Nov 4, 2026 |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$0.86 → $0.57 · observed estimates
$0.41B → $0.09B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $0.86 | $408,217,000 | 2 / 1 |
| 2026-07-25 | $0.86 | $408,217,000 | 2 / 1 |
| 2026-07-26 | $0.86 | $408,217,000 | 2 / 1 |
| 2026-07-27 | $0.86 | $408,217,000 | 2 / 1 |
| 2026-07-28 | $0.86 | $408,217,000 | 2 / 1 |
| 2026-07-29 | $0.79 | $82,684,000 | 1 / 1 |
| 2026-07-30 | $0.86 | $408,217,000 | 2 / 1 |
| 2026-07-31 | $0.79 | $82,684,000 | 1 / 1 |
| 2026-08-01 | $0.79 | $82,684,000 | 1 / 1 |
| 2026-08-02 | $0.86 | $408,217,000 | 2 / 1 |
| 2026-08-03 | $0.86 | $408,217,000 | 2 / 1 |
| 2026-08-04 | $0.79 | $82,684,000 | 1 / 1 |
| 2026-08-05 | $0.79 | $82,684,000 | 1 / 1 |
| 2026-08-06 | $0.79 | $82,684,000 | 1 / 1 |
| 2026-08-07 | $0.79 | $82,684,000 | 1 / 1 |
| 2026-08-08 | $0.86 | $408,217,000 | 2 / 1 |
| 2026-08-09 | $0.79 | $82,684,000 | 1 / 1 |
| 2026-08-10 | $0.79 | $82,684,000 | 1 / 1 |
| 2026-08-12 | $0.79 | $82,684,000 | 1 / 1 |
| 2026-08-13 | $0.79 | $82,684,000 | 1 / 1 |
| 2026-08-14 | $0.79 | $82,684,000 | 1 / 1 |
| 2026-08-15 | $0.79 | $82,684,000 | 1 / 1 |
| 2026-08-16 | $0.79 | $82,684,000 | 1 / 1 |
| 2026-08-17 | $0.79 | $82,684,000 | 1 / 1 |
| 2026-08-18 | $0.79 | $82,684,000 | 1 / 1 |
| 2026-08-19 | $0.79 | $82,684,000 | 1 / 1 |
| 2026-08-20 | $0.53 | $87,218,000 | 1 / 1 |
| 2026-08-21 | $0.53 | $87,218,000 | 1 / 1 |
| 2026-08-22 | $0.53 | $87,218,000 | 1 / 1 |
| 2026-08-23 | $0.53 | $87,218,000 | 1 / 1 |
| 2026-08-24 | $0.53 | $87,218,000 | 1 / 1 |
| 2026-08-25 | $0.53 | $87,218,000 | 1 / 1 |
| 2026-08-26 | $0.53 | $87,218,000 | 1 / 1 |
| 2026-08-27 | $0.53 | $87,218,000 | 1 / 1 |
| 2026-08-28 | $0.53 | $87,218,000 | 1 / 1 |
| 2026-08-29 | $0.57 | $94,112,000 | 1 / 1 |
| 2026-08-30 | $0.57 | $94,112,000 | 1 / 1 |
| 2026-08-31 | $0.57 | $94,112,000 | 2 / 1 |
| 2026-09-01 | $0.57 | $94,112,000 | 2 / 1 |
| 2026-09-02 | $0.57 | $94,112,000 | 2 / 1 |
| 2026-09-03 | $0.57 | $94,112,000 | 2 / 1 |
| 2026-09-04 | $0.57 | $94,112,000 | 2 / 1 |
| 2026-09-05 | $0.57 | $94,112,000 | 2 / 1 |
| 2026-09-06 | $0.57 | $94,112,000 | 2 / 1 |
| 2026-09-07 | $0.57 | $94,112,000 | 2 / 1 |
| 2026-09-08 | $0.57 | $94,112,000 | 2 / 1 |
| 2026-09-09 | $0.57 | $94,112,000 | 2 / 1 |
| 2026-09-10 | $0.57 | $94,112,000 | 2 / 1 |
| 2026-09-11 | $0.57 | $94,112,000 | 2 / 1 |
| 2026-09-12 | $0.57 | $94,112,000 | 2 / 1 |
| 2026-09-13 | $0.57 | $94,112,000 | 2 / 1 |
| 2026-09-14 | $0.57 | $94,112,000 | 2 / 1 |
| 2026-09-15 | $0.57 | $94,112,000 | 2 / 1 |
| 2026-09-16 | $0.57 | $94,112,000 | 2 / 1 |
| 2026-09-17 | $0.57 | $94,112,000 | 2 / 1 |
| 2026-09-18 | $0.57 | $94,112,000 | 2 / 1 |
| 2026-09-19 | $0.57 | $94,112,000 | 2 / 1 |
| 2026-09-20 | $0.57 | $94,112,000 | 2 / 1 |
| 2026-09-21 | $0.57 | $94,112,000 | 2 / 1 |
| 2026-09-22 | $0.57 | $94,112,000 | 2 / 1 |
| 2026-09-23 | $0.57 | $94,112,000 | 2 / 1 |
| 2026-09-24 | $0.57 | $94,112,000 | 2 / 1 |
| 2026-09-25 | $0.57 | $94,112,000 | 2 / 1 |
| 2026-09-26 | $0.57 | $94,112,000 | 2 / 1 |
| 2026-09-27 | $0.57 | $94,112,000 | 2 / 1 |
| 2026-09-28 | $0.57 | $94,112,000 | 2 / 1 |
| 2026-09-29 | $0.57 | $94,112,000 | 2 / 1 |
| 2026-09-30 | $0.57 | $94,112,000 | 2 / 1 |
| 2026-10-01 | $0.57 | $94,112,000 | 2 / 1 |
| 2026-10-02 | $0.57 | $94,112,000 | 2 / 1 |
| 2026-10-03 | $0.57 | $94,112,000 | 2 / 1 |
| 2026-10-04 | $0.57 | $94,112,000 | 2 / 1 |
| 2026-10-05 | $0.57 | $94,112,000 | 2 / 1 |
| 2026-10-06 | $0.57 | $94,112,000 | 2 / 1 |
| 2026-10-07 | $0.57 | $94,112,000 | 2 / 1 |
| 2026-10-08 | $0.57 | $94,112,000 | 2 / 1 |
| 2026-10-09 | $0.57 | $94,112,000 | 2 / 1 |
| 2026-10-10 | $0.57 | $94,112,000 | 2 / 1 |
| 2026-10-11 | $0.57 | $94,112,000 | 2 / 1 |
| 2026-10-12 | $0.57 | $94,112,000 | 2 / 1 |
| 2026-10-13 | $0.57 | $94,112,000 | 2 / 1 |
| 2026-10-14 | $0.57 | $94,112,000 | 2 / 1 |
| 2026-10-15 | $0.57 | $94,112,000 | 2 / 1 |
| 2026-10-16 | $0.57 | $94,112,000 | 2 / 1 |
| 2026-10-17 | $0.57 | $94,112,000 | 2 / 1 |
| 2026-10-18 | $0.57 | $94,112,000 | 2 / 1 |
| 2026-10-19 | $0.57 | $94,112,000 | 2 / 1 |
| 2026-10-20 | $0.57 | $94,112,000 | 2 / 1 |
| 2026-10-21 | $0.57 | $94,112,000 | 2 / 1 |
| 2026-10-22 | $0.57 | $94,112,000 | 2 / 1 |
| 2026-10-23 | $0.57 | $94,112,000 | 2 / 1 |
| 2026-10-24 | $0.57 | $94,112,000 | 2 / 1 |
| 2026-10-25 | $0.57 | $94,112,000 | 2 / 1 |
| 2026-10-26 | $0.57 | $94,112,000 | 2 / 1 |
| 2026-10-27 | $0.57 | $94,112,000 | 2 / 1 |
| 2026-10-28 | $0.57 | $94,112,000 | 2 / 1 |
| 2026-10-29 | $0.57 | $94,112,000 | 2 / 1 |
| 2026-10-30 | $0.57 | $94,112,000 | 2 / 1 |
| 2026-10-31 | $0.57 | $94,112,000 | 2 / 1 |
| 2026-11-01 | $0.57 | $94,112,000 | 2 / 1 |
| 2026-11-02 | $0.57 | $94,112,000 | 2 / 1 |
| 2026-11-03 | $0.57 | $94,112,000 | 2 / 1 |
| 2026-11-04 | $0.57 | $94,112,000 | 2 / 1 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 3 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.